391 related articles for article (PubMed ID: 32820119)
1. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.
Fluckiger A; Daillère R; Sassi M; Sixt BS; Liu P; Loos F; Richard C; Rabu C; Alou MT; Goubet AG; Lemaitre F; Ferrere G; Derosa L; Duong CPM; Messaoudene M; Gagné A; Joubert P; De Sordi L; Debarbieux L; Simon S; Scarlata CM; Ayyoub M; Palermo B; Facciolo F; Boidot R; Wheeler R; Boneca IG; Sztupinszki Z; Papp K; Csabai I; Pasolli E; Segata N; Lopez-Otin C; Szallasi Z; Andre F; Iebba V; Quiniou V; Klatzmann D; Boukhalil J; Khelaifia S; Raoult D; Albiges L; Escudier B; Eggermont A; Mami-Chouaib F; Nistico P; Ghiringhelli F; Routy B; Labarrière N; Cattoir V; Kroemer G; Zitvogel L
Science; 2020 Aug; 369(6506):936-942. PubMed ID: 32820119
[TBL] [Abstract][Full Text] [Related]
2. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer: any room left for immunotherapies?
Baxevanis CN; Fortis SP; Perez SA
Immunotherapy; 2019 Feb; 11(2):69-74. PubMed ID: 30727800
[No Abstract] [Full Text] [Related]
4. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Šmahel M
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
[TBL] [Abstract][Full Text] [Related]
5. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
6. T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors.
Sioud M
Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29381830
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
[TBL] [Abstract][Full Text] [Related]
8. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
9. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
10. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
[TBL] [Abstract][Full Text] [Related]
11. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
12. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.
Blake J; Johnston JV; Hellström KE; Marquardt H; Chen L
J Exp Med; 1996 Jul; 184(1):121-30. PubMed ID: 8691125
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
[TBL] [Abstract][Full Text] [Related]
14. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
Huang AY; Golumbek P; Ahmadzadeh M; Jaffee E; Pardoll D; Levitsky H
Science; 1994 May; 264(5161):961-5. PubMed ID: 7513904
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
16. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L
J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283
[TBL] [Abstract][Full Text] [Related]
17. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
19. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
